Project Details
Description
INFLAMMATION AND THE METABOLIC SYNDROME IN PSYCHOSIS
ABSTRACT TEXT
The metabolic syndrome (MetS) is a constellation of metabolic risk factors associated with the development
of atherosclerotic cardiovascular disease morbidity and mortality. The MetS is highly common in patients
with psychosis, and cardiovascular disease is the leading cause of mortality in this patient population. The
MetS is also associated with a state of low-grade inflammation. Blood white blood cell (WBC) counts—even
within the normal range—serve as a marker of inflammation. Psychosis is associated with increased
inflammation, including increased total and differential WBC counts. The adverse metabolic effects of
atypical antipsychotics, which increase MetS risk, may potentiate aberrant levels of blood inflammatory
markers. Several large population-based samples found that total and differential WBC counts were
associated with risk of the MetS and its individual criteria. Compared to the general population, relatively less
is known about associations between inflammation and the MetS in psychosis, especially whether baseline
levels of inflammatory markers predict incident metabolic adverse effects of antipsychotic treatment. This
application addresses these important knowledge gaps. The primary goals are to perform systematic
reviews and meta-analyses of the relationship between inflammation and prevalent and incident MetS in
patients with psychosis, including unpublished data from the Open Translational Science in Schizophrenia
(OPTICS) Project, an open-science initiative between Janssen and the NIMH. This R03 application: 1) Has
Aims congruent with NIMH's strategic focus on clinically useful biomarkers that predict change across the
trajectory of illness, 2) Is a rigorously designed systematic review and meta-analysis using unpublished data
from the OPTICS Project to investigate a novel potential biomarker that may identify—prior to treatment—
patients with psychosis at heightened risk for incident adverse cardiometabolic effects of antipsychotics, and
represents a “next-step” towards personalized medicine approaches for these patients, and 3) Supports the
career transition of an L30 and K23 awardee to an R-series Investigator, consistent with the NIH's Next
Generation Researchers Initiative.
Status | Not started |
---|
Funding
- National Institute of Mental Health
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.